Myeloma Investment Fund (MIF)

Myeloma Investment Fund (MIF)

Invests in early-stage multiple myeloma drug and technology companies, recycling returns into further health innovation investments.

The Myeloma Investment Fund (MIF) is a wholly-owned evergreen venture philanthropy subsidiary of the Multiple Myeloma Research Foundation (MMRF), established in 2019 to make equity investments in early-stage biotechnology companies developing novel myeloma therapies and technologies. MIF has committed USD 23 million across 21 portfolio companies since founding, with 17 companies currently active and 6 portfolio treatments having advanced to clinical trials as of 2026. All financial returns from the fund are 100 percent reinvested into MIF, enabling continuous compounding of capital for myeloma research investment. The model parallels the Cystic Fibrosis Foundation's CF Ventures arm — a disease-focused foundation deploying patient-advocacy capital into commercial biotech rather than traditional grant mechanisms.

MIF invests exclusively in companies pursuing innovative therapies and technologies for multiple myeloma — the second most common blood cancer in the United States. Eligible companies must be for-profit biotech or life science entities; academic researchers, nonprofits, and individuals are not eligible for MIF equity investment. There is no published minimum or maximum check size. MIF considers both US-based and international companies, provided the therapeutic or technology focus is directly relevant to myeloma patients. The fund provides capital alongside strategic guidance, leveraging MMRF's extensive network of myeloma researchers, oncologists, and pharmaceutical partners.

MIF does not operate a public request-for-proposals process or an open application portal. Companies seeking investment must make direct contact with the MIF team via the web form at myelomainvestmentfund.org/contact/ or by phone at (203) 229-0464. MMRF and MIF are headquartered at 383 Main Avenue, 7th Floor, Norwalk, CT 06851. Companies should present evidence of strong myeloma science, a credible path to transformative patient benefit, and a business model capable of generating financial returns that sustain the fund's evergreen reinvestment strategy.